Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01080664
Other study ID # 27335
Secondary ID
Status Terminated
Phase Phase 1
First received March 2, 2010
Last updated October 21, 2013
Start date December 2006
Est. completion date August 2011

Study information

Verified date October 2013
Source EMD Serono
Contact n/a
Is FDA regulated No
Health authority Switzerland: EthikkommissionBelgium: Institutional Review BoardItaly: Ethics CommitteeGermany: Ethics CommissionUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.


Description:

The goal of this research study is to investigate for the first time the safety and tolerability of a new drug (AS703569), called an aurora kinase inhibitor, being tested to treat blood cancers in patients with different blood cancers. The research study will also assess how the body breaks down AS703569 and what changes occur in the blood after oral doses of AS703569. It will also look to see if there is any improvement in your blood cancer. The use of AS703569 in this study is experimental.


Recruitment information / eligibility

Status Terminated
Enrollment 124
Est. completion date August 2011
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Dose-escalation part:

- Primary or secondary acute myeloid leukaemia, including subjects:

with first or subsequent relapse after standard therapy, with no established treatment options; refractory to available therapies, e.g. who failed to achieve complete remission after chemotherapies; Newly-diagnosed elderly subjects (over 60 years) according to WHO classification (=20 blasts in bone marrow), who did not accept or were not eligible for chemotherapy (first line therapy)

- Subjects with myelodysplastic syndrome (IPSS Int-2 or high risk) resistant or intolerant to standard treatment and not candidates for allogeneic HSCT.

- Subjects with chronic myeloid leukaemia in chronic, accelerated or blast-phase, resistant or intolerant to standard treatment and not candidates for allogeneic HSCT.

- Subjects with myeloproliferative disorders and no effective treatment options.

- Subjects with acute lymphoblastic leukaemia, relapsing, resistant or intolerant to standard treatment and no effective treatment options.

- Subjects with chronic lymphocytic leukaemia, relapsing, resistant or intolerant to standard treatment and no effective treatment options.

- Subjects with non-Hodgkin lymphoma, relapsing, resistant or intolerant to standard treatment with no effective treatment options.

Cohort expansion part

- Primary or secondary acute myeloid leukaemia not eligible for chemotherapy (first line therapy), including subjects

with first or subsequent relapse after standard therapy, for whom no established treatment options are available; refractory to available therapies, e.g. who failed to achieve complete remission after chemotherapies; Newly-diagnosed elderly subjects (over 60 years) according to WHO classification (= 20 blasts in bone marrow), who did not accept or were not eligible for chemotherapy (first line therapy)

- Subjects with chronic myeloid leukaemia in chronic or accelerated phase, resistant or intolerant to standard treatment, who have not achieved a complete haematological response, and are not candidates for allogeneic HSCT.

- Subjects with myeloproliferative disorders with no effective treatment options.

- Subjects with Philadelphia chromosome positive acute leukaemias including acute lymphoblastic leukaemia and blast phase chronic myeloid leukaemia, relapsing, resistant or intolerant to standard treatment with no effective treatment options.

Exclusion Criteria:

- Acute promyelocytic leukaemia.

- Ongoing uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.

- Hyperleukocytosis with >50x10(9)/L leukaemic blasts.

- Chemotherapy, immunotherapy, biologic therapy or any experimental anti-cancer therapy within 28days prior to study Day1 and/or not having recovered from its toxicity.

- Extensive radiotherapy involving =30% of bone marrow (e.g. whole pelvis, half spine) within 6months prior to study Day1.

- Active CNS disease involvement.

- Any condition, including laboratory, medical history or pre-study assessment findings, that in the opinion of the Investigator, constitute a risk or contraindication for participation or that could interfere with the study objectives, conduct or evaluation of a drug to be taken orally.

- Clinically relevant cardiac abnormalities or clinically relevant abnormalities .

- Known infection with human immunodeficiency virus, active hepatitis B, or hepatitis C.

- Signs and symptoms suggestive of transmissible spongiform encephalopathy.

- Major surgery within 2weeks prior to study Day1.

- Haemoglobin <8g/dL at screening (can be transfused).

- Refractory to platelet transfusion (defined as increase of <20.109/L platelets 1hour after transfusion).

- Coexistent second malignancy or history of prior malignancy within previous 3years (excluding basal or squamous cell carcinoma of the skin, and in situ carcinoma of the cervix that has been treated curatively).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
AS703569
Dose Escalation Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle: Number of cycles: until progression or unacceptable toxicity develops. Cohort Expansion Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle: Number of cycles: until progression or unacceptable toxicity develops
AS703569
Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops. Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.

Locations

Country Name City State
Belgium Haematologie UZ Gasthuisberg Leuven
Belgium Mont-Godinne University Hospital (UCL) Yvoir
Germany Universitatsklinik Frankfurt Frankfurt am Main
Germany Technische Universitat Munchen Munchen
Germany Medizinische Universitatsklinik Ulm
Italy Policlinico Sant'Orsola Malpighi Bologna
Switzerland Kantonsspital Basel Basel
Switzerland Hospitaux Universitaires Geneva
Switzerland Kantonsspital St Gallen St Gallen
United States CTRC at the UT Health Science Center at San Antonio San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
EMD Serono

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Italy,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-Limiting Toxicity (DLT) Dose-escalation part - The number of subjects experiencing at least a Dose-Limiting Toxicity (DLT), judged to be related to the study medication, evaluated over the first cycle only for each dose level and regimen, independently. 21 days or 1 cycle No
Primary Preliminary anti-tumour activity Cohort expansion part - Preliminary anti-tumour activity in four selected cohorts of haematological malignancies as assessed every two cycles 42 days or 2 cycles No
Secondary Treatment-emergent adverse events (TEAE) Dose-escalation and Cohort expansion parts The proportion/number of subjects experiencing treatment-emergent adverse events (TEAE) after the first cycle and during multiple cycles, in each cohort for each of the 2 dose-regimens. minimum 21 days or 1 cycle No
See also
  Status Clinical Trial Phase
Recruiting NCT01719341 - Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia N/A
Terminated NCT04865419 - Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies Phase 1
Completed NCT01827579 - Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT) Phase 1/Phase 2
Suspended NCT02988258 - Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT Phase 1
Completed NCT05148806 - Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
Withdrawn NCT01336478 - CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation Phase 1